Knowledge gaps and future opportunities for biologics in childhood allergic and immunologic disorders - 03/03/23
Doi : 10.1016/j.jaci.2023.01.003
Cullen M. Dutmer, MD a, Andrew H. Liu, MD b, ⁎ 
a Allergy and Immunology Section, Children’s Hospital Colorado and University of Colorado School of Medicine, Aurora, Colo
b the Pediatric Pulmonary and Sleep Medicine Section, and Breathing Institute, Children’s Hospital Colorado and University of Colorado School of Medicine, Aurora, Colo
∗Corresponding author: Andrew H. Liu, MD, Children's Hospital Colorado, 13123 E 16th Ave, Box B395, Aurora, CO 80045.Children's Hospital Colorado13123 E 16th AveBox B395AuroraCO80045
Key words : Asthma, exacerbation, immune deficiency, inborn errors of immunity, biologic therapy, biomarker
Le texte complet de cet article est disponible en PDF.
Plan
| Supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (grants UM1 AI114271 [Inner-City Asthma Consortium-3], UM1 AI160040 [CAUSE], U01 AI160033 [CAUSE]), and R01 AI098077 [Gill] [to C.M.D. and A.H.L.]); the National Heart, Lung, and Blood Institute (grant P01 HL132821 [PPG]); and the National Center for Advancing Translational Sciences (grant UL1 TR002535 [Colorado CTSA]). |
|
| Disclosure of potential conflict of interest: C. M. Dutmer reports personal fees from Enzyvant Therapeutics and Horizon Therapeutics outside the submitted work. A. H. Liu reports grants and nonfinancial support from ResMed Propeller Health, nonfinancial support from Revenio, grants and personal fees from Avillion, and personal fees from Phadia ThermoFisher and LabCorp, outside the submitted work. |
© 2023
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 151 - N° 3
P. 691-693 - mars 2023 Retour au numéro
Article précédent
- Immunodeficiency secondary to biologics
- Roxane Labrosse, Elie Haddad
- In search of the Holy Grail in atopic dermatitis: Will dupilumab become the first disease-modifying atopic dermatitis drug?
- Thomas Bieber
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?